Newsroom
Featured News
- Business20 February 2025
Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis®
- Business11 February 2025
Lotus Announces TFDA Approval for Adcirca® (Tadalafil) for PAH Treatment
- Investors10 February 2025
Lotus Reported Unaudited January Revenues of NT$2,171 million
- Investors10 January 2025
Lotus Achieves Historical High with Unaudited 2024 Revenue of NT$18.6 Billion
- Business07 January 2025
Lotus Announces the Closing of the Alphachymotrypsine Choay® Acquisition, Ready to consolidate revenue from Q1 2025
- Investors10 December 2024
Lotus Reported Unaudited November Revenues of NT$1,061 million, YTD Revenue Surpassing the Total Revenue for 2023
- Investors07 November 2024
Lotus Reported Unaudited October Revenues of NT$1,885 million
- Investors07 November 2024
Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results
- Investors06 November 2024
Lotus pharmaceuticals 3Q24 earnings call
